Congress poster: ESGO 2026 Efficacy of elinzanetant in VMS associated with endocrinetherapy: OASIS-4 subgroup analyses

Bayer AG 2026 Open access

Read full text
Authors: Donal J. Brennan, Nick Panay, Fatima Cardoso, Paula Briggs, Gilbert G.G. Donders, Nazanin Haseli Mashhadi, Cecilia Caetano, Maja Francuski, Claudia Haberland, Kaisa Laapas, Christian Seitz, Lineke Zuurman
DOI: 10.71943/bayer.figshare.31293535
Cited by: 0

Abstract

Poster presented at ESGO 2026 to communicate results of analysis that evaluated the effect of elinzanetant for VMS frequency across BMI and smoking history subgroups in the OASIS-4 study. Elinzantant treatment resulted in numerically greater reductions vs placebo in VMS frequency across all BMI and smoking history subgroups from baseline to week 12

Fields of Study & Subjects

Menopause: Health Impacts and Treatments Estrogen and related hormone effects Advanced Breast Cancer Therapies

Publication details

Journal / source
Bayer AG
Publication date
26 February 2026
Language
EN